Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Regeneron Pharmaceuticals Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regeneron (REGN), Celldex (CLDX) and Nurix Therapeut...

Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Celldex (CLDX) and Nurix Therapeutics (NRIX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Valneva (VALN), Regeneron (REGN) and Telix Pharmaceu...

Analysts Are Bullish on These Healthcare Stocks: Valneva (VALN), Regeneron (REGN)

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals has finished a mid stage study tes...

Regeneron’s POTS Study Wraps Up: What REGN7544 Could Mean for REGN Investors

Regeneron Pharmaceuticals ($REGN), Sanofi ($SNYNF) announced an update on their ongoing clinical study. The study, officially titled “PRospEctiVe c...

Real-World Asthma Data on Dupixent: What Regeneron and Sanofi Investors Should Know

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alumis Inc. (ALMS), Glaukos (GKOS) and Regeneron (...

Analysts Conflicted on These Healthcare Names: Alumis Inc. (ALMS), Glaukos (GKOS) and Regeneron (REGN)

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Targets Fatty Liver Disease With New Phase 2a Stud...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	REGN	$656.01	+0.63%	708.39K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	REGN	$656.01	+0.6%	708.39K
3
4
5
6

REGN

REGN

Get Regeneron Pharmaceuticals Inc. Data in Excel

Get Regeneron Pharmaceuticals Inc. Data in Excel